Hot Life Science Investor Mandate 1: CRO Looking to Leverage Service for Equity

1 May

An international life science investment group based in the eastern US is looking to invest invests in life science companies by using its product development and CRO services effectively as a capital investment. The firm has the ability to leverage 30-70% of the development cost in exchange for equity, downstream royalties, etc. The firm places a strong emphasis in the technology and will invest in companies that are based in the USA, UK, Europe, The Middle East, and Asia. The firm is actively seeking new investment opportunities. 

The firm is currently seeking to invest in biotech therapeutics, diagnostics, and medical devices. For therapeutics, the firm seeks both biologics and small molecule assets that are in pre-clinical through to phase III of clinical trials. For medical devices, the firm is also opportunistic in terms of subsectors and only invests in companies with at least a prototype that is ready for clinic. The firm is open to all indications including orphan indications.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

%d bloggers like this: